Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1101743
Abstract: Background: In clinical studies, some patients who achieve deep molecular response (DMR) can successfully discontinue tyrosine kinase inhibitor (TKI). TKI dose reduction is also an important aspect of alleviating adverse effects and improving quality of… read more here.
Keywords: full dose; dose reduction; discontinuation; treatment ... See more keywords